London Calling 2024 - Speakers
A
Dr. Ahmad Abou TayounAl Jalila Children’s Specialty Hospital & Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, UAE
Antoni P.A. HendrickxNational Institute for Public Health and the Environment, Netherlands
Andre HolzerHolzer Scientific Consultancy, Germany
Anoushka JoglekarNew York Genome Center, USA
Adrien LegerDirector, Modified Base Research, Oxford Nanopore Technologies
Alex ShawImperial College London, UK
Alex TrotterDevelopment Scientist – Translational Development, Oxford Nanopore Technologies
Alexander WittenbergKeyGene, Netherlands
Akelia Wauchope-OdumboAssociate Director, Technical Applications — Americas, Oxford Nanopore Technologies
B
Bryant CatanoSenior Product Support Scientist, Oxford Nanopore Technologies
Prof. Benjamin KippMayo Clinic, USA
Bosheng LiInstitute of Advanced Agricultural Sciences, Peking University, China
Ben PriceNatural History Museum, UK
C
Claire AndersonUniversity College London, UK
Chris AlderBioinformatician, Oxford Nanopore Technologies
Clive BrownChief Technology, Innovation, and Product Officer, Oxford Nanopore Technologies
Chao Chun LiuSimon Fraser University, Canada
Dr. Charles K. CooperbioMérieux, France
Dr. Clemens JakobiLonza, Switzerland
Dr. Carolyn TregidgoVP, Late Stage and Applied Product Development, Oxford Nanopore Technologies
D
Daniel BrantonHarvard University, USA
David W. DeamerUniversity of California, Santa Cruz, USA
Dan FordhamDirector, Strategic Product Management EMEA, Oxford Nanopore Technologies
Dr. Danny E. MillerUniversity of Washington, USA
Devin OglesbeeMayo Clinic, USA
E
Prof. Emma BapleUniversity of Exeter and South West NHS Genomics Laboratory Hub, UK
Ethan Hill‘Iolani School, USA
Emma WhiteVP, Marketing Operations, Oxford Nanopore Technologies
Eddy de BoerUniversity Medical Center Groningen, Netherlands
H
Dr. Helen Bulbeckbrainstrust, UK
Hagan BayleyUniversity of Oxford, UK
Dr. Helen GunterBASE mRNA Facility, The University of Queensland, Australia
Hanlee JiStanford University, USA
Heather Ritchie-ParkerRoyal Zoological Society of Scotland, UK
I
Prof. Ian AbbsGuy’s and St Thomas’ NHS Foundation Trust, UK
Dr. Inès HassanTony Blair Institute for Global Change, UK
J
Jessica AndersonSenior Field Applications Scientist, Oxford Nanopore Technologies
Prof. Sir John BellEllison Institute of Technology Oxford, UK
Jimmy CreithField Applications Scientist, Bioinformatics, Oxford Nanopore Technologies
Julie DragonUniversity of Vermont, USA
Dr. Janessa LaskinBC Cancer Centre & University of British Columbia, Canada
Joanne TrinhInstitute of Neurogenetics, University of Lübeck, Germany
Prof. Joris VermeeschKU Leuven, Belgium
Jose-Crispin Zavala AlvaradoPathoQuest, France
K
Kimberley BillingsleyNational Institutes of Health, USA
Kara DicksProgramme Manager, Conservation Genomics—ORG.ONE, Oxford Nanopore Technologies
Dr. Karen SherwoodUniversity of British Columbia, Canada
Katharina WolffTU Braunschweig, Germany
L
Lyn ChittyGreat Ormond Street NHS Foundation Trust & UCL Great Ormond Street Institute of Child Health, UK
Lauren LuiLawrence Berkeley National Laboratory, USA
Dr. Luke W. MeredithWHO-EMRO World Health Emergencies, Egypt
Dr. Luca MazzarellaEuropean Institute of Oncology, Italy
Prof. Laurent MesnardSorbonne University, France
Lorey SmithPeter MacCallum Cancer Centre, Australia
Lara UrbanHemholtz AI, Germany
M
Medini AnnavajhalaColumbia University Irving Medical Center, USA
Mark AkesonUniversity of California, Santa Cruz, USA
Prof. Matt BrownGenomics England, UK
Morgan GueuningBlood Transfusion Service, Switzerland
Morghan LucasMedical Genetics Center, Germany
Michael NakaiPeter MacCallum Cancer Centre, Australia
Dr. Matt ParkerDirector, Clinical Bioinformatics Software, Oxford Nanopore Technologies
Mile SikicGenome Institute of Singapore, A*STAR, Singapore
Mrinalini WatsaSan Diego Zoo Wildlife Alliance, USA
N
Natalia GarciaBioinformatics Workflow Developer, Oxford Nanopore Technologies
Ndack NdiayePasteur Institute, Senegal
Nick SeddonOptum Genomics, USA
P
Paul ArvidsonGenomics England & SWAN, UK
Ping LuPeking University, China
Prof. Dr. Pieter WesselingPrincess Máxima Center for Pediatric Oncology & Amsterdam University Medical Centers, The Netherlands
R
Dr. Rahul BatraGuy's and St Thomas' NHS Foundation Trust UK
Rui ChenBaylor College of Medicine, USA
Rea KobialkaInstitute of Animal Hygiene and Veterinary Public Health, Germany
Rachel RubinsteinTechnical Product Manager, Software, Oxford Nanopore Technologies
Rosemary Sinclair DokosSVP, Product and Programme Management, Oxford Nanopore Technologies
Rhys WhiteInstitute of Environmental Science and Research, New Zealand
S
Sergey BatalovRady Children’s Institute for Genomic Medicine, USA
Seanne P. BuckwalterMayo Clinic, USA
Sam DavisPrincipal Scientist, Machine Learning, Oxford Nanopore Technologies
Sneha GoenkaStanford University & Princeton University, USA
Sarah GriffithsBioinformatics Workflow Developer, Oxford Nanopore Technologies
Sirisha HeskethClinical Bioinformatician, Oxford Nanopore Technologies
Sofia KudashevaEarlham Institute, UK
Susie LeeTechnical Product Manager, Basecalling and Models, Oxford Nanopore Technologies
Sean McKenzieAssociate Director, Genomic Applications Bioinformatics, Oxford Nanopore Technologies
Dr. Simon PaineNottingham University Hospitals NHS Trust, UK
Steph WilbrahamDirector, Automation Product Management, Oxford Nanopore Technologies
Spike WillcocksChief Strategy Officer, Oxford Nanopore Technologies
T
Thias Oberg BoesenNovo Nordisk A/S, Denmark
Tomás Di DomenicoNational Cancer Research Center, Spain
Tomasz DobrzyckiField Applications Scientist, New Product Introduction, Oxford Nanopore Technologies
Dr. Telmo GraçaLonza, Switzerland
Tina HanTwist Bioscience
Dr. Thomas R. KreilTakeda, Austria
Tetyana VasylyevaUniversity of California, Irvine, USA
Tjakko van HamErasmus University Medical Center, Netherlands
Oxford Nanopore Technologies
Spike Willcocks
- Job title
- Institution
- Chief Strategy Officer, Oxford Nanopore Technologies
- Biography
After studying Chemistry at the University of Oxford and completing a DPhil in Biochemistry, Spike started working for the intellectual property investment business “IP Group” in 2001 as an early employee.
He ultimately led its Life Sciences group, and was responsible for the formation of Oxford Nanopore Technologies during that time. Gordon persuaded Spike to join Oxford Nanopore full time at the start of 2006, leading the Corporate and Business development function, and now he is the company’s Chief Strategy Officer.